Meta-analysis of 9 RCTs (668 patients) with cancer-related fatigue: methylphenidate slightly reduced fatigue v placebo (SMD 0.23), with no significant increase in adverse events; trial sequential analysis found insufficient information to confirm.
Meta-analysisn = 668
Wen et al. Methylphenidate in improving cancer-related fatigue: efficacy and safety - systematic review and meta-analysis of randomised controlled trials with trial sequential analysis